1.–67. (Canceled)

68. A pharmaceutically acceptable salt of a compound which is:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

69.–73. (Canceled)

74. A method for the treatment of a cancerous cell growth mediated by raf kinase comprising administering a pharmaceutically acceptable salt of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

75.–79. (Canceled)

80. A method for the treatment of solid cancers comprising administering to a host an effective amount of a pharmaceutically acceptable salt of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

81. A method for the treatment of carcinomas, myeloid disorders or adenomas comprising administering to a host an effective amount of a pharmaceutically acceptable salt of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

82.–86. (Canceled)

87. A method for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon comprising administering to a host an effective amount of a pharmaceutically acceptable salt of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

88.–92. (Canceled)

93. A method for the treatment of myeloid leukemia or villous colon adenomas comprising administering to a host an effective amount of a pharmaceutically acceptable salt of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

94.–98. (Canceled)

99. A method as in claim 74 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

100.–109. (Canceled)

110. (New) A method for the treatment of a cancerous cell growth comprising administering to a host an effective amount of a pharmaceutically acceptable salt of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

111. A method as in claim 110 wherein the pharmaceutically acceptable salt is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

112. A method as in claim 80 wherein the pharmaceutically acceptable salt is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

113. A method as in claim 81 wherein the pharmaceutically acceptable salt is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

114. A method as in claim 87 wherein the pharmaceutically acceptable salt is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

115. A method as in claim 93 wherein the pharmaceutically acceptable salt is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

116. A method as in claim 74 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

117. A method as in claim 110 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

118. A method as in claim 80 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

119. A method as in claim 81 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N*'-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

120. A method as in claim 87 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N*'-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

121. A method as in claim 93 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.

122. A pharmaceutically acceptable salt of claim 68 which is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

123. A pharmaceutically acceptable salt of claim 68 which is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

124. A pharmaceutically acceptable salt which is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,

N-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea; or

N-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea.